Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc.

TNDM
Tandem Diabetes Care, Inc.US flagNASDAQ Global Market
16.91
USD
-0.69
- -
1.16BMarket Cap
Tandem Diabetes Care, Inc.
TNDM
(NASDAQ Global Market)

Recent

price

16.91

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
1.97
98.6
21.37
25.19
27.56
18.95
3.82
6.19
8.18
11.16
12.49
11.51
14.36
15.08
15.16
Revenue per Share
-20.34
-26.32
-214.61
-34.17
-25.04
-27.3
-12.86
-2.55
-0.42
-0.56
0.25
-1.47
-3.43
-1.47
-3.04
-1.39
Basic EPS, GAAP
-18.23
-31.09
-182.76
-28.34
-22.34
-22.93
-12.66
-0.23
0.38
-0.13
1.39
0.12
-1.97
0.08
-1.61
-0.57
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-57.99
-84.55
-575.01
-106.86
-111.02
-132.34
-84.13
-12.47
-10.68
-10.81
-10.07
-11.37
-14.65
-16.01
-18.61
-18.78
Book Value per Share
-56.84
-86.96
383.55
22.4
21.21
-2.52
-5.39
2.7
3.32
5.86
6.77
6.79
4.78
4.01
2.13
1.95
Tangible Book Value per Share
1
1
- -
2
3
3
6
48
59
61
63
64
65
65
67
68
Basic Weighted Avg Shares
- -
2
29
50
73
84
108
184
362
499
703
801
748
940
1,015
1,028
Sales/Revenue/Turnover
- -
-1,335.27
-170.42
-152.17
-94.72
-92.64
-58.5
-24.27
-4.62
-1.6
3.22
-11.59
-31.19
-10.54
-16.49
-6.22
Operating Margin (%)
1
2
3
4
5
5
7
6
6
10
14
14
16
17
18
18
Depreciation Expense
-26
-33
-63
-80
-72
-83
-73
-123
-25
-34
16
-95
-223
-96
-205
-95
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.11
- -
- -
- -
- -
112.58
Effective Tax Rate (%)
- -
-1,333.94
-217.67
-159.94
-99.41
-99.05
-67.87
-66.68
-6.83
-6.89
2.21
-11.81
-29.77
-10.21
-20.17
-9.2
Profit Margin (%)
-7
11
134
73
80
61
28
122
177
533
680
685
553
477
375
639
Working Capital
- -
- -
29
29
29
79
77
- -
14
219
305
407
399
415
425
715
LT Debt
-71
-106
116
55
63
-6
-29
131
195
366
433
440
314
263
155
132
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.32
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-5.27
- -
- -
- -
- -
19.2
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
21
19
20
LT Borrowings
310
310
602
LT Finance Leases
118
115
113
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
68
69
Market Capitalization
810
1,479
1,299

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
617
618
887
Cash, Cash Equivalents & STI
319
293
570
Accounts Receivable, Net
126
165
141
Inventories
137
129
126
Total Current Liabilities
253
243
248
Payables & Accruals
60
68
79
ST Debt
21
19
20
Deferred Revenue
10
10
9

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-19.76%
-13.2%
-41.02%
Free Cash Flow
-602.58%
-1,104.12%
-2,267.74%
Net Income, GAAP
-63.16%
-132.26%
113.18%
Sales/Revenue/Turnover
33.09%
16.38%
7.93%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
192
222
244
283
940
2025
234
241
249
290
1,015
2026
247
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.65
-0.47
-0.35
0.01
-1.47
2025
-1.97
-0.78
-0.31
-0.01
-3.04
2026
-0.3
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) designs, develops, manufactures and commercializes advanced automated insulin delivery systems and related products for people with insulin-dependent diabetes, including type 1 and type 2 diabetes; its core offerings include the t:slim X2 insulin pump with integrated color touchscreen and Control-IQ+ advanced hybrid closed-loop technology featuring predictive algorithms with AutoBolus capability for ages 2+ (type 1) and 18+ (type 2), the Tandem Mobi system as a compact tubeless insulin pump with smartphone control (iOS), 200-unit insulin capacity, Dexcom G6/G7 continuous glucose monitoring compatibility and inductive wireless charging, infusion sets with varied cannula materials, tubing lengths and insertion angles, t:connect diabetes management software for data visualization and remote software updates, and innovative mobile/cloud-based applications for therapy monitoring; the company also provides 24/7 support, expert training and limited warranties. Founded in 2006 and headquartered in San Diego, California, Tandem operates globally with sales in the United States and international markets, targeting people with diabetes, healthcare providers and distribution channels including durable medical equipment and pharmacy rebates covering approximately 20% of U.S. lives; it maintains partnerships with Dexcom for CGM integration, Abbott, Unomedical (Convatec) for infusion sets and the University of Virginia Center for Diabetes Technology for fully automated closed-loop research. Recent developments include U.S. FDA clearance for Control-IQ+ expansion to type 2 diabetes patients, successful 2024 U.S. launch of Tandem Mobi via multi-channel strategy with quarter-over-quarter shipment growth, completion of the 2024 Tandem Choice program, return to positive free cash flow, maintenance of full-year revenue guidance at $1 billion with double-digit growth focus, international shift to direct sales for higher average selling prices, sales force expansion, planned 2026 commercial launch of tubeless Mobi to capture type 2 market share, and 2023 acquisition of AMF Medical SA to integrate the Sigi rechargeable patch pump technology into its portfolio.

Company News

APIChatGPT
  • Does TNDM Stock Still Deserve a Place in Your Portfolio?

  • Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets

  • Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026

  • Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026

  • Tandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

  • Wall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High?

  • Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy

  • Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy

  • Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now

  • 3 Stocks to Invest in as Broker Rating Upgrades Signal Upside

  • Tandem Diabetes Valuation: Is 1.1x Sales a Buy?

  • TNDM Stock: What to Know About Tandem's 2026 Reset

  • Tandem Diabetes Care Inc (TNDM) Shares Surge 12.9% -- What GF Score of 62 Tells Investors

  • Silver Economy Investing: Why the Healthcare Giants Are in Focus

  • TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up

  • Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • Tandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

  • Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript

  • Tandem Diabetes Care Q1 Earnings Call Highlights

  • Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates